KURA
Price:
$8.94
Market Cap:
$695.21M
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a ...[Read more]
Industry
Biotechnology
IPO Date
2015-09-16
Stock Exchange
NASDAQ
Ticker
KURA
According to Kura Oncology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 662.36M. This represents a change of -58.42% compared to the average of 1.59B of the last 4 quarters.
The mean historical Enterprise Value of Kura Oncology, Inc. over the last ten years is 566.88M. The current 662.36M Enterprise Value has changed 11.58% with respect to the historical average. Over the past ten years (40 quarters), KURA's Enterprise Value was at its highest in in the June 2024 quarter at 1.81B. The Enterprise Value was at its lowest in in the March 2015 quarter at -5811000.00.
Average
566.88M
Median
521.79M
Minimum
3.52M
Maximum
1.42B
Discovering the peaks and valleys of Kura Oncology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.83%
Maximum Annual Enterprise Value = 1.42B
Minimum Annual Increase = -95.32%
Minimum Annual Enterprise Value = 3.52M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.03B | 30.16% |
2022 | 793.57M | -6.10% |
2021 | 845.13M | -40.61% |
2020 | 1.42B | 154.96% |
2019 | 558.12M | 14.97% |
2018 | 485.46M | 38.23% |
2017 | 351.19M | 225.37% |
2016 | 107.93M | 58.74% |
2015 | 67.99M | 1.83% |
2014 | 3.52M | -95.32% |
The current Enterprise Value of Kura Oncology, Inc. (KURA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
890.54M
5-year avg
930.54M
10-year avg
566.88M
Kura Oncology, Inc.’s Enterprise Value is less than Protagonist Therapeutics, Inc. (2.30B), less than Merus N.V. (2.48B), less than Replimune Group, Inc. (892.33M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than KalVista Pharmaceuticals, Inc. (400.99M), less than Crinetics Pharmaceuticals, Inc. (4.74B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Viridian Therapeutics, Inc. (1.38B), less than Gracell Biotechnologies Inc. (5.66B), greater than Monte Rosa Therapeutics, Inc. (356.78M), greater than Design Therapeutics, Inc. (323.81M), less than Erasca, Inc. (685.22M), less than Cogent Biosciences, Inc. (777.97M), greater than Larimar Therapeutics, Inc. (222.97M), less than Kiniksa Pharmaceuticals, Ltd. (1.38B), less than Day One Biopharmaceuticals, Inc. (859.59M), greater than Inozyme Pharma, Inc. (215.58M), greater than Zentalis Pharmaceuticals, Inc. (225.76M), less than Syndax Pharmaceuticals, Inc. (1.00B),
Company | Enterprise Value | Market cap |
---|---|---|
2.30B | $2.42B | |
2.48B | $2.91B | |
892.33M | $929.70M | |
8.24B | $8.19B | |
400.99M | $436.36M | |
4.74B | $5.00B | |
138.26M | $181.50M | |
1.38B | $1.56B | |
5.66B | $989.87M | |
356.78M | $438.66M | |
323.81M | $351.62M | |
685.22M | $701.16M | |
777.97M | $857.19M | |
222.97M | $252.67M | |
1.38B | $1.46B | |
859.59M | $1.28B | |
215.58M | $193.36M | |
225.76M | $226.62M | |
1.00B | $1.14B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kura Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kura Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Kura Oncology, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Kura Oncology, Inc. (KURA)?
What is the 3-year average Enterprise Value for Kura Oncology, Inc. (KURA)?
What is the 5-year average Enterprise Value for Kura Oncology, Inc. (KURA)?
How does the current Enterprise Value for Kura Oncology, Inc. (KURA) compare to its historical average?